Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)

被引:0
|
作者
Laux, L.
Devinsky, O.
Miller, I
Nabbout, R.
Zolnowska, M.
Wright, S.
Roberts, C.
机构
关键词
Epilepsy; Rare Diseases;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
47
引用
收藏
页码:S344 / S344
页数:1
相关论文
共 50 条
  • [41] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [43] LONG-TERM EFFICACY AND SAFETY OF LANADELUMAB: FINAL RESULTS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Banerji, A.
    Hao, J.
    Yu, M.
    Bernstein, J.
    Johnston, D.
    Riedl, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S21 - S21
  • [44] Long-term safety and efficacy of Clobazam for Lennox Gastaut syndrome (LGS): 2-year results of an open label extension (OLE) study
    Ng, Y. T.
    Conry, J. A.
    Paolicchi, J. M.
    Kernitsky, L.
    Mitchell, W. G.
    Drummond, R.
    Austin, S. A.
    Weinberg, M. A.
    Owen, J. R.
    ANNALS OF NEUROLOGY, 2011, 70 : S140 - S140
  • [45] Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
    McElvaney, Noel G.
    Burdon, Jonathan
    Holmes, Mark
    Glanville, Allan
    Wark, Peter A. B.
    Thompson, Philip J.
    Hernandez, Paul
    Chlumsky, Jan
    Teschler, Helmut
    Ficker, Joachim H.
    Seersholm, Niels
    Altraja, Alan
    Makitaro, Riitta
    Chorostowska-Wynimko, Joanna
    Sanak, Marek
    Stoicescu, Paul I.
    Piitulainen, Eeva
    Vit, Oliver
    Wencker, Marion
    Tortorici, Michael A.
    Fries, Michael
    Edelman, Jonathan M.
    Chapman, Kenneth R.
    LANCET RESPIRATORY MEDICINE, 2017, 5 (01): : 51 - 60
  • [46] Safety of Long-Term Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis up to 172 Weeks: Results from an Open-Label Extension (OLE) Trial
    Wollenberg, Andreas
    Beck, Lisa
    Deleuran, Mette Sondergaard
    Blauvelt, Andrew
    Thyssen, Jacob
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal
    Rodriguez-Marco, Ainara
    Levit, Noah
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB10 - AB10
  • [47] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) trial up to 4 years
    Wollenberg, Andreas
    Soong, Weily
    Goooderham, Melinda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB106 - AB106
  • [48] Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
    Thompson, William R.
    Manuel, Ryan
    Abbruscato, Anthony
    Carr, Jim
    Campbell, John
    Hornby, Brittany
    Vaz, Frederic M.
    Vernon, Hilary J.
    GENETICS IN MEDICINE, 2024, 26 (07)
  • [49] Efficacy and Safety of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC) in Pediatric Patients Enrolled in a Phase 3 Trial With an Open-Label Extension (OLE)
    Thiele, E.
    Lawson, J.
    Kotulska, K.
    Sahebkar, F.
    Greco, T.
    Saurer, T.
    ANNALS OF NEUROLOGY, 2023, 94 : S57 - S57
  • [50] Efficacy and Safety of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC) in Pediatric Patients Enrolled in a Phase 3 Trial With an Open-Label Extension (OLE)
    Thiele, E.
    Lawson, J.
    Kotulska, K.
    Sahebkar, F.
    Greco, T.
    Saurer, T.
    ANNALS OF NEUROLOGY, 2023, 94 : S55 - S55